Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyUrologic OncologyDiseaseNeuroendocrine CarcinomaProstate CancerSubgroupATM-MutationBRCA mutationcastration resistantDNA Repair Defecthormone sensitiveICD10C61C80.9MeSHCarcinoma, NeuroendocrineProstatic DiseasesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantSequenceARASENS: DOCE75/PRED5/DARO600/GOSE10.8, Prostate Ca (HS), A (PID2040) -|- B (PID2041) -|- C (PID2081)DGRL240, Prostate Ca, C1 (PID1524) -|- DGRL80, C2+ (PID1525)DOCE75/PRED5/GOSE10.8, Prostate Ca (HS), A (PID641) -|- B (PID664) -|- C (PID2082)HERO: RELU(360/120), Prostate Ca, C1 (PID2250) -|- RELU120, C2+ (PID2247).PEACE-1: DOCE75/PRED5/ABIR1000/GOSE10.8, Prostate Ca (HS), A (PID2305) -|- B (PID2306) -|- C (PID2307).ChemotherapyChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances12357Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurative or palliativedisease controlpalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaBone PainCardiotoxicityConstipationDepressionDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFractureGynecomastiaHeadacheHeart FailureHematuriaHepatotoxicityHyperglycemiaHyperhidrosisHyperkalemiaHypertensionHypokalemiaHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsLeukopeniaLibido ReductionMuscle WeaknessNauseaNeuropathyNeutropeniaOral MucositisOsteopeniaPainParesthesiaPneumoniaRashRenal FailureSpinal Cord CompressionThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAgarwal NApostolidis LBeer TBolton EMChi KChi KNClarke NWCorn PG Davis IDde Bono JDe Bono Jde Bono JSEisenberger MFizazi KHellmann MDKellokumpu-Lehtinen PKlotz LOudard SRomero-Laorden NRyan CScher HShore NDSmith MRSternberg CNSweeney JCTannock ITannock IFDiseaseFortgeschrittenes hormonsensitives Prostatakarzinomfortgeschrittenes oder metastasiertes Prostata-Ca, kastrationsresistent, ECOG 0-2Fortgeschrittenes Prostatakarzinomkastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2metastasiertes, hormonresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, Karnofsky > 60metastasiertes, hormonsensitives Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-2metastasiertes, hormonsensitives Prostata KarzinomMetastasiertes, hormonsensitives Prostata KarzinomMetastasiertes, hormonsensitives ProstatakarzinomMetastasiertes, kastrationsresistentes Prostata-Ca, Progress unter Abirateron/Prednisolon, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, symptomatisch, ECOG 0-3metastasiertes, kastrationsresistentes Prostata-Ca mit BRCA1, BRCA2, oder ATM Mutation, Progress nach Androgenrezeptor-Antagonisten der 2. GenerationMetastasiertes, kastrationsresistentes Prostatakarzinom, asymptomatisch oder wenig Symptome, ECOG 0-1metastasiertes, kastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2metastasiertes, kastrationsresistentes Proststa Karzinom nach Docetaxel Therapie, ECOG 0-2Metastasiertes hormonsensitives Prostatakarzinom, ECOG 0-1Metastasiertes hormonsensitives Prostatakarzinom, ECOG 0-2, mindestens 2 von 3 Kriterien positiv: Gleason Score gleich oder höher 8; 3 oder mehr Knochenmetastasen; viszerale Metastasen.Metastasiertes kastrationsresistentes Prostata-Ca, ErstlinieMetastasiertes kastrationsresistentes Prostata-Ca, Erstlinie, HRR+Metastasiertes kastrationsresistentes Prostata-Ca, progredient nach Therapie mit z.B. Enzalutamid oder AbirateronMetastasiertes kastrationsresistentes Prostatakarzinom, ECOG 0-2metastasiertes kastrationsresistentes Prostatakarzinom, Erstlinie, ECOG 0-2neudiagnostiziertes Prostatakarzinom, metastasiert, hormonsensitiv, ECOG 0-2Neuroendokrines Prostatakarzinom, Erst- und Zweitlinienicht metastasiertes, kastrationsresistentes Hochrisiko Prostata-Canicht metastasiertes, kastrationsresistentes Prostata-Ca, ECOG 0-1nicht metastasiertes, kastrationsresistentes Prostata-Ca, PSA-Verdopplungszeit weniger als 10 Monate, ECOG 0-1Prostatakarzinom, alle Stadien, ECOG 0-2Originassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialCarolina Urologic Research Center, Myrtle Beach, SC, HERO trialDepartment of Medical Oncology, University Hospital HeidelbergDepartment of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, TAX 327 InvestigatorsDepartment of Medicine and the Department of Biostatics and Computational Biology, Dana Farber Cancer Institute, BostonDepartment of Oncology, Tampere University Hospital, Tampere, Finland, PROSTY study groupDepartment of Urology, St James's Hospital, Dublin, IrelandDepartment of Urology, St James Hospital, Dublin, IrelandEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA, PROSPER trialGenitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, COU-AA-302 InvestigatorsGeorge Pompidou European Hosptial, Paris, FIRSTANAGustave Roussy, University of Paris Sud, Villejuif, France, LATITUDE trialGustave Roussy Institute, Paris-Saclay University, Villejuif, France, TRITON3 trialHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA, TALAPRO-2 trialInstitute of Cancer Research and Royal Marsden Hospital, Sutton, COU-AA-301 InvestigatorsInstitute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom, PROfound trialInstitut Gustave Roussy, Universite Paris-Sud, Villejuif, France, ARAMIS trialInstitut Gustave Roussy, University of Paris-Saclay, Villejuif, France, PEACE-1Massachusetts General Hospital Cancer Center, BostonMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialMemorial Sloan-Kettering Cancer Center, New York, AFFIRM trialMonash University, Australia, ENZAMET TRIALOHSU Knight Cancer Institute, Oregon Health and Science University, PREVAIL trialPrincess Margaret Hospital, Toronto, CanadaRoyal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK, TROPICSpanish National Cancer Research Centre (CNIO), Madrid, Spain, SWITCH trialThe Johns Hopkins University, Baltimore, PROSELICAUniversity of British Columbia, CancerdVancouver Center, Vancouver, Canada, MAGNITUDE trialUniversity of Manchester, Manchester, United Kingdom, PROpel trialUniversity of Paris Sud, Villejuif, France, LATITUDE StudieUniversity of Texas MD Anderson Cancer Center, Houston, USAUniversity of Toronto, CanadaVancouver Prostate Centre, Vancouver, Canada, TITANProtocols in Revision 44 protocols foundProtocols under revision.Abiraterone 1000 / Dexamethasone 0.5, Prostate Cancer Castration Resistant (PID2311)Abiraterone 1000 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer, First Line (PID1002)Abiraterone 1000 / Prednisolone 5, Prostate Cancer Hormone Sensitive (PID1504)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, First Line (PID919)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, Second Line (PID920)Apalutamide 240, Prostate Cancer hormone sensitive (PID1503)Apalutamide 240, Prostate Cancer Castration Resistant (PID1232)Buserelin 9.45, Prostate Cancer (PID1523)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, First Line (PID1129)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, Second Line (PID1134)Cabazitaxel 25 / Carboplatin 4 / Prednisolone 5 Prostate Cancer (PID2310)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, First Line (PID1104)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, Second Line (PID645)Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283)Darolutamide 600, Prostate Cancer Castration Resistant (PID1642)Degarelix 240, Prostate Cancer, Cycle 1 (PID1524)Degarelix 80, Prostate Cancer, Cycle 2+ (PID1525)Docetaxel 30 / Prednisolone 5, Prostate Cancer (PID1391)Docetaxel 50 / Prednisolone 10, Prostate Cancer (PID941)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8 -Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part C (PID2307)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID2305)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID2306)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8 - Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2081)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, part A (PID2040)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part B (PID2041)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8 - Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2082)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID641)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID664)Docetaxel 75 / Prednisolone 5, Prostate Cancer (PID921)Enzalutamide 160 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, First Line (PID1360)Enzalutamide 160, Prostate Cancer Castration Resistant (PID1557)Enzalutamide 160, Prostate Cancer castration-resistant, first-line (PID918)Enzalutamide 160, Prostate Cancer castration-resistant, second-line (PID917)Goserelin 10.8, Prostate Cancer (PID1520)Leuprorelin 11.25, Prostate Cancer (PID1521)Mitoxantrone 12 / Prednisolone 5, Prostate Cancer castration resistant (PID2309)Niraparib 200 / Abiraterone 1000 / Prednisolone 10, Prostate Cancer castration-resistant (PID2557)Olaparib 300 / Abiraterone 1000 / Prednisolone 5, Prostate Cancer castration resistant (PID2326)Olaparib 300, Prostate Cancer Castration Resistant (PID1559)Relugolix (360/120), Prostate Cancer, Cycle 1 (PID2250)Relugolix 120, Prostate Cancer, Cycle 2+ (PID2247)Rucaparib 600, Prostate Cancer Castration Resistant (PID2308)Talazoparib 0.5 / Enzalutamide 160, Prostate Cancer castration-resistant (PID2556)Triptorelin 11,25, Prostate Cancer (PID1522)
